Valeant Pharmaceuticals International Inc. has seen a sharp drop in third-quarter profit despite a healthy increase in revenue.

Canada’s largest publicly traded drug maker reported Friday that its net income for the three months ended Sept. 30 fell to just $7.6-million(U.S.) or 2 cents per diluted share.

That compared with net earnings of $40.9-million or 13 cents in the same 2011 period.

Revenue soared to $884.1-million from $570. 4 million.

On a cash EPS basis, adjusted income was $357.5-million, or $1.15 per diluted share. Analysts expected Valeant’s adjust earnings to be $1.12 per share based on 17 estimates compiled by Thomson Reuters.

Revenue was estimated at $873.35-million, based on 15 estimates.

Valeant has made more than a dozen acquisitions this year to help strengthen its position as a global leader in dermatology products, including the recent purchase of U.S.-based Medicis Pharmaceutical Corp. for $2.6-billion.

Valeant also bought Dermik, a dermatological unit of Sanofi in the U.S. and Canada that manufactures, markets and sells a range of therapeutic and aesthetic dermatology products.

Last year, it bought Edmonton-based Afex Life Sciences, maker of the popular over-the-counter cold and flu remedy Cold-FX.

Another acquisition was iNova, which sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Southeast Asia and South Africa.

Valeant, formed from the combination of California-based Valeant and the former Biovail pharmaceutical company, announced in April that it would move its global headquarters to Quebec to focus on over-the-counter dermatology products. It’s also setting up a research and development centre for consumer dermatology in Laval, north of Montreal.